Protalix BioTherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 14, 2022 at 11:50 am
Share
Protalix BioTherapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported revenue was USD 14.18 million compared to USD 12.05 million a year ago. Net loss was USD 3.57 million compared to USD 4.2 million a year ago. Basic loss per share from continuing operations was USD 0.07 compared to USD 0.09 a year ago.
For the nine months, revenue was USD 39.02 million compared to USD 29.8 million a year ago. Net loss was USD 11.19 million compared to USD 20.92 million a year ago. Basic loss per share from continuing operations was USD 0.24 compared to USD 0.48 a year ago.
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of severe gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its product, Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase)- a chemically modified enzyme under development for the potential treatment of severe gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate.
PROTALIX BIOTHERAPEUTICS, INC. 
